|
|
Article: Agennix Reports Positive NSCLC Data With Talactoferrin, Chemo.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Agennix Inc. said its recombinant human lactoferrin product, talactoferrin, showed substantially improved response rates in patients with non-small-cell lung cancer when combined with first-line chemotherapy.
Results from the 110-patient Phase II trial, presented at the 96th annual meeting of the American Association for Cancer Research in Anaheim, Calif., also reported the drug was safe and well tolerated.
As the first company to produce commercial quantities of human lactoferrin for pharmaceutical purposes, Agennix has several ongoing Phase II trials in cancer and wound treatment for talactoferrin alfa, an immunostimulatory ...